Celldex Therapeutics Inc (CLDX) USD0.001
Sell:$16.85Buy:$21.59
$1.30
(7.16%)
- This stock can be held in a
Stocks and Shares ISA$1.30
(7.16%)$1.30
(7.16%)Company Information
About this company
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Key people
Key facts
- EPICCLDX
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS15117B2025
- Market cap$1.32bn
- Employees186
- Shares in issue66.38m
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.